EM1807F “The Prevention of Type 1 Diabetes” (IM GR-071318)
The purpose of this Grand Rounds is to update the efforts to prevent or alter the course of type 1 diabetes. There is considerable interest and research efforts being expended in order to prevent the disease or slow its progression. I plan to discuss the work that is being done in that regard.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand that the frequency of type 1 diabetes is increasing
- Understand the new classification of type 1 diabetes and that the disease begins when an individual has two or more diabetes specific immune markers in their blood
- Understand the effect of age at diagnosis has on the progression of type 1 diabetes
- Be aware of the studies that attempt to alter the course of type 1 diabetes after a clinical diagnosis has been made
- Be aware of the studies that attempt to alter the course of type 1 diabetes, before a clinical diagnosis has been made.
Philip Raskin, M.D.
Professor of Internal Medicine
Clifton and Betsy Robinson Chair in Biomedical Research
Division of Endocrinology
Philip Raskin, M.D. received his medical degree from the University of Pittsburgh, School of Medicine and completed a residency in Internal Medicine there. He did a Fellowship in Endocrinology, Diabetes and Metabolism at UT Southwestern Medical Center at Dallas. He is board certified in Internal Medicine and Endocrinology, Diabetes and Metabolism. He is a Fellow of the American College of Physicians and the American College of Endocrinology, and is a Certified Diabetes Educator.
He is presently Professor of Medicine, Department of Internal Medicine and holds the Clifton and Betsy Robinson Chair in Biomedical Research at the University of Texas Southwestern Medical Center at Dallas. He is an Attending Physician in the Diabetes Clinic at Parkland Health and Hospital Systems and the Parkland Memorial Hospital. He is the Principal Investigator in four NIH funded multicenter diabetes trials: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), TrialNet, The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study) and Vitamin D to Prevent Type 2 Diabetes (D2d Study).
- 1.00 AMA